Navigation Links
Halozyme Reports First Quarter 2012 Financial Results
Date:5/7/2012

ater convenience to patients versus the traditional IV method due to its less invasive administration route and quicker administration time (5 minutes versus 30 – 90 minutes).  
  • Roche reiterated their intent to file the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the EMA this year for the treatment of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma.
  • Announced positive data with ViroPharma regarding a Phase 2 SC trial of Cinryze® (C1 esterase inhibitor [human]) in combination with rHuPH20, in patients with hereditary angioedema. Presented at the American Academy of Allergy Asthma & Immunology, the study demonstrated that SC co-administration of Cinryze with rHuPH20 was well tolerated and resulted in sustained physiologically relevant C1 INH functional concentrations.
  • Updated the Hylenex® recombinant (hyaluronidase human injection) label to include instructions for pre-administration of the enzyme in advance of other injected or subcutaneously infused drugs, and information from non-clinical studies that provide further data on the safety profile of Hylenex.

    • First Quarter 2012 Financial ResultsThe net loss for the first quarter of 2012 was $15.1 million, or $0.14 per share, compared with a net loss for the first quarter of 2011 of $9.6 million, or $0.10 per share.

  • Revenues for the first quarter of 2012 were $7.4 million, compared to $7.5 million for the first quarter of 2011. Revenues in the first quarter of 2012 primarily consisted of a milestone payment from Roche of $4 million and research and development reimbursements from partners.
  • Research and development expenses for the first quarter of 2012 were $15.9 million, compared with $13.8 million for the first quarter of 2011, primarily due to an increase in manufacturing activities and compensation costs, partially offset by a decrease in clinical trial act
    '/>"/>

    • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
    3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
    4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
    5. Halozyme Announces Proposed Public Offering of Common Stock
    6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
    7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
    9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
    11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
    (Date:5/17/2013)... , May 17, 2013 ... developer of oral drug delivery systems, announced today that ... cleared the Company,s Investigational New Drug application(IND) for ORMD-0801, ... pleased to have the FDA clearance to proceed," stated ... "The upcoming trial is a major milestone for Oramed ...
    (Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
    Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
    ... , Feb. 11 The American Academy of Pain ... Presidential Commendations and Awards presented by the Academy,s Immediate Past President, ... recipients were recognized at AAPM,s 26th Annual Meeting held in ... physicians convened to learn the latest in Pain Medicine. , ...
    ... , , CAMBRIDGE, Mass. , ... SHPGY ), the global specialty biopharmaceutical company, today presented positive ... and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy ... were presented in an oral presentation at the Lysosomal Disease ...
    Cached Medicine Technology:The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 2The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 3The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 4Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 2Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 3Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 4Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 5Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 6Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 7
    (Date:5/19/2013)... Dr. Keith Chertok now provides gum disease patients with a ... the chance of a healthier smile. Laser gum surgery ... only removes diseased gum tissue in patients, but it also ... dental implants. , LANAP uses a laser to successfully ... stimulate the healthy tissue as well as encourage new bone ...
    (Date:5/19/2013)... Exciting new Skin Brushes are available from ... practice known through the ages but is a lost ... brushing, has so many benefits for our health and ... love that circulation and lymphatic systems get a boost ... is supported through Skin Brushing." , Why is Skin ...
    (Date:5/19/2013)... 2013 HealthEconomics.Com , the global ... to unveil a new and exciting service: HE-Xpo: a ... powerful array of real-time communication tools to expand their ... abroad. , HE-Xpo is powered by OnStream Media’s ... and feel of being at a physical trade show, ...
    (Date:5/18/2013)... Columbia (PRWEB) May 19, 2013 In “Cooking ... (published by iUniverse) , author Janet Hall Svisdahl’s new cookbook, ... recipes sure to make even the pickiest eater drool. ... pleasurably and prayerfully,” she explains. , Found within the ... a wide range of delicious recipes, from fast and simple ...
    (Date:5/18/2013)... Angeles, California (PRWEB) May 18, 2013 ... surgery is an increasingly popular weight loss surgery that ... Lap Band Center wishes to give readers ... , Dr. Naim attended medical school at New York ... at New York Methodist he undertook a fellowship in ...
    Breaking Medicine News(10 mins):Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3
    ... Ill. An automated system for measuring brain tissue ... accurately diagnose Alzheimer,s disease at an earlier stage according ... of the journal Radiology . , In Alzheimer,s ... areas of the brain, especially the hippocampus region, to ...
    ... Looms in Charlotte, Cincinnati,Cleveland, Dallas-Ft. Worth, Kansas City, ... ARLINGTON, Va., June 23 The American,Association ... competitive,bidding program for home medical equipment in order ... continuity of care for seniors and people,with disabilities. ...
    ... Than $150 Million in New Revenue for,Medicaid, WASHINGTON, ... to resolve a projected state budget deficit, a,report released ... would,raise more than $150 million in new revenue to ... smokers to quit, reduce,tobacco-related health care costs and save ...
    ... Benefit TAC, ARLINGTON, Va., June ... ,3066584/ref=pd_bbs_sr_1?ie=UTF8&s=books&qid=1213968063&sr=8-1 ), E. Fuller,Torrey, M.D.,s latest ... the greatest social,disasters in recent American ... hundreds,of thousands of patients with severe ...
    ... cost may still be prohibitive, experts say , , MONDAY, June ... deposits accurately predicts the overall death risk for American adults, ... best predictor we have of who will have a problem ... associate professor of medicine at the Harbor-UCLA Medical Center. , ...
    ... China, June 23 /Xinhua-PRNewswire/ -- China Medicine,Corporation ... "the Company"),a leading distributor and developer of ... nutritional and dietary supplements,medical devices, and medical ... today announced it has successfully obtained the ...
    Cached Medicine News:Health News:Automated MRI technique assists in earlier Alzheimer's diagnosis 2Health News:American Association for Homecare Recommends Needed Improvements to Medicare Competitive Bidding Program, Set to Begin July 1 2Health News:American Association for Homecare Recommends Needed Improvements to Medicare Competitive Bidding Program, Set to Begin July 1 3Health News:New Report: Increasing Mississippi's Cigarette Tax Will Reduce Smoking, Save Lives and Save Money 2Health News:Dr. Torrey Takes 'The Insanity Offense' 2Health News:Arterial Calcium Scans Can Predict Death Risk 2Health News:Arterial Calcium Scans Can Predict Death Risk 3Health News:Arterial Calcium Scans Can Predict Death Risk 4Health News:China Medicine Maintains Exclusive Rights to Distribute 2,300 Pharmaceutical Products 2Health News:China Medicine Maintains Exclusive Rights to Distribute 2,300 Pharmaceutical Products 3
    Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
    Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
    Use this workhorse apron where 360 of protection from direct and scatter radiation is required....
    Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
    Medicine Products: